Quizartinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Quizartinib" in English language version.

refsWebsite

Global rank English rank

8web.archive.org

1^st place

6nih.gov

4^th place

3doi.org

2^nd place

3fda.gov

447^th place

338^th place

3europa.eu

68^th place

117^th place

1daiichisankyo.com

low place

1medpagetoday.com

9,274^th place

5,856^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1handle.net

102^nd place

76^th place

clinicaltrials.gov

"Quizartinib studies". Archived from the original on 21 February 2017. Retrieved 20 February 2017.

daiichisankyo.com

"Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML" (Press release). Archived from the original on 10 August 2023. Retrieved 16 February 2021.

doi.org

Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. (December 2009). "Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor". Journal of Medicinal Chemistry. 52 (23): 7808–7816. doi:10.1021/jm9007533. PMID 19754199.
Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, et al. (July 2005). "Internal tandem duplications of the FLT3 gene are present in leukemia stem cells". Blood. 106 (2): 673–80. doi:10.1182/blood-2004-05-1902. PMC 1895185. PMID 15797998.
Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM (March 2013). "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms". Molecular Cancer. 12: 19. doi:10.1186/1476-4598-12-19. PMC 3637582. PMID 23497317.

europa.eu

ema.europa.eu

"Vanflyta EPAR". European Medicines Agency. 21 November 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Vanflyta". European Medicines Agency. 6 January 2020. Archived from the original on 27 January 2023. Retrieved 6 August 2023.

ec.europa.eu

"Vanflyta Product information". Union Register of medicinal products. 7 November 2023. Archived from the original on 13 November 2023. Retrieved 13 November 2023.

fda.gov

"FDA approves quizartinib for newly diagnosed acute myeloid leukemia". U.S. Food and Drug Administration (FDA). 20 July 2023. Archived from the original on 21 July 2023. Retrieved 21 July 2023. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Vanflyta". U.S. Food and Drug Administration (FDA). 20 July 2023. Retrieved 18 April 2024. This article incorporates text from this source, which is in the public domain.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

handle.net

hdl.handle.net

World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl:10665/74683.

medpagetoday.com

"Drug Tames Refractory AML. ASH Dec 2012". 9 December 2012. Archived from the original on 8 August 2014. Retrieved 16 December 2012.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, et al. (December 2009). "Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor". Journal of Medicinal Chemistry. 52 (23): 7808–7816. doi:10.1021/jm9007533. PMID 19754199.
Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, et al. (July 2005). "Internal tandem duplications of the FLT3 gene are present in leukemia stem cells". Blood. 106 (2): 673–80. doi:10.1182/blood-2004-05-1902. PMC 1895185. PMID 15797998.
Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM (March 2013). "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms". Molecular Cancer. 12: 19. doi:10.1186/1476-4598-12-19. PMC 3637582. PMID 23497317.

ncbi.nlm.nih.gov

Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L, et al. (July 2005). "Internal tandem duplications of the FLT3 gene are present in leukemia stem cells". Blood. 106 (2): 673–80. doi:10.1182/blood-2004-05-1902. PMC 1895185. PMID 15797998.
Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Döhner H, Döhner K, Schittenhelm MM (March 2013). "Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms". Molecular Cancer. 12: 19. doi:10.1186/1476-4598-12-19. PMC 3637582. PMID 23497317.

dailymed.nlm.nih.gov

"Vanflyta- quizartinib tablet, film coated". DailyMed. 26 July 2023. Archived from the original on 7 August 2023. Retrieved 6 August 2023.

web.archive.org

"Vanflyta- quizartinib tablet, film coated". DailyMed. 26 July 2023. Archived from the original on 7 August 2023. Retrieved 6 August 2023.
"FDA approves quizartinib for newly diagnosed acute myeloid leukemia". U.S. Food and Drug Administration (FDA). 20 July 2023. Archived from the original on 21 July 2023. Retrieved 21 July 2023. This article incorporates text from this source, which is in the public domain.
"Vanflyta EPAR". European Medicines Agency. 21 November 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Vanflyta Product information". Union Register of medicinal products. 7 November 2023. Archived from the original on 13 November 2023. Retrieved 13 November 2023.
"Daiichi Sankyo Launches FLT3 Inhibitor Vanflyta in Japan for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML" (Press release). Archived from the original on 10 August 2023. Retrieved 16 February 2021.
"Drug Tames Refractory AML. ASH Dec 2012". 9 December 2012. Archived from the original on 8 August 2014. Retrieved 16 December 2012.
"Quizartinib studies". Archived from the original on 21 February 2017. Retrieved 20 February 2017.
"Vanflyta". European Medicines Agency. 6 January 2020. Archived from the original on 27 January 2023. Retrieved 6 August 2023.